Evercore ISI Group Maintains In-Line on Quest Diagnostics, Lowers Price Target to $210

Benzinga Newsdesk www.benzinga.com Negative 65.9%

Neg 65.9% Neu 0% Pos 0%

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Line and lowers the price target from $220 to $210.